My watch list
my.chemeurope.com  
Login  

Alatrofloxacin



Alatrofloxacin
Systematic (IUPAC) name
7-[(1R,5S)-6-{[(2S)-1-{[(2S)-2-aminopropanoyl]amino}-
1-oxopropan-2-yl]amino}-3-azabicyclo[3.1.0]hexan-3-yl]-
1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-
3-carboxylic acid
Identifiers
CAS number 157182-32-6
157605-25-9 (mesylate)
ATC code  ?
PubChem 5489474
Chemical data
Formula C26H25F3N6O5 
Mol. mass 558.509 g/mol
Pharmacokinetic data
Bioavailability N/A
Protein binding 76% (trovafloxacin)
Metabolism Quickly hydrolyzed to trovafloxacin
Half life 9 to 12 hours (trovafloxacin)
Excretion Fecal and renal (trovafloxacin)
Therapeutic considerations
Pregnancy cat.

C(US)

Legal status

Withdrawn

Routes Intravenous

Alatrofloxacin (Trovan IV) is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt.[1] It is the parental prodrug of trovafloxacin (Trovan) meant for intravenous administration. Trovafloxacin is a broad-spectrum antibiotic introduced in 1998 which encountered criticism for its Nigerian trials and adverse clinical reactions.[2][3]

Additional recommended knowledge

Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in 2001.

References

  1. ^ PubChem CID 5489474.
  2. ^ Hall IH, Schwab UE, Ward ES, Ives TJ (2003). "Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes". Biomed. Pharmacother. 57 (8): 359–65. PMID 14568230.
  3. ^ Lenzer J (2006). "Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests". BMJ 332 (7552): 1233. doi:10.1136/bmj.332.7552.1233-a. PMID 16735322.
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Alatrofloxacin". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE